PremiumThe FlyKezar Life Sciences reports Q1 EPS ($2.27), consensus ($2.65) Kezar Life Sciences Appoints New Principal Accounting Officer Kezar Life Sciences: Promising AIH Phase II Results and Strategic FDA Engagement Justify Buy Rating PremiumThe FlyKezar Life Sciences files $400M mixed securities shelf Kezar Life Sciences price target lowered to $9 from $11 at Wells Fargo Kezar Life Sciences reports Q3 EPS ($2.78), consensus ($3.15) PremiumThe FlyBiotech Alert: Searches spiking for these stocks today Kezar Life Sciences receives $1.10 per share acquisition proposal from Concentra Biotech Alert: Searches spiking for these stocks today 
